Taylor Fields

I am the Chief Development Officer & President, Product Development of IntrabBio Inc., a biotechnology company discovering and developing novel treatments for rare and common neurodegenerative disorders.

I have over a decade of pharmaceutical experience working in the United States, Europe/UK, Asia, and Australia, including early-stage translational work, mid-stage clinical development, and commercial launch. 

At IntraBio, I lead all efforts related to the development and commercialisation of IntraBio’s novel treatment and therapies for rare and common neurodegenerative disorders, and am principally responsible for the company’s research, clinical, and regulatory activities. 

I was responsible for leading the development program of N-acetyl-L-leucine (AQNEURSA), the first monotherapy to receive approval by the US Food and Drug Administration for the treatment of Niemann-Pick disease type C. 

I have an undergraduate degree from the University of Michigan and a Master's of Studies from the University of Oxford.